Table 3:
Functional Outcomes After TAVI or SAVR in PARTNER Trial, Cohort A, Intention-to-Treat Analysisa
| Author, Year | NYHA Functional Class I/II Among Survivors, N (%) | Quality of Life, Mean (SD) | |||
|---|---|---|---|---|---|
| KCCQ Summary | SF-12 Physical | SF-12 Mental | EQ-5D Utilities | ||
|
Baseline Smith et al, 201120 Reynolds et al, 201230 |
TAVI: 20 (5.7) SAVR: 21 (6.0) |
TF-TAVI: 39.3 (21.7) SAVR: 43.8 (22.6) |
TF-TAVI: 29.7 (7.7) SAVR: 30.6 (8.1) |
TF-TAVI: 47.0 (11.5) SAVR: 47.1 (11.0) |
TF-TAVI: 0.66 (0.2) SAVR: 0.66 (0.21) |
| TA-TAVI: 40.3 (22.1) SAVR: 46.2 (19.8) |
TA-TAVI: 29.4 (7.4) SAVR: 31.7 (8.5) |
TA-TAVI: 46.6 (11.4) SAVR: 48.7 (9.6) |
TA-TAVI: 0.67 (0.19) SAVR: 0.72 (0.17) |
||
| Mean Change From Baseline (95% CI) | |||||
|
30 days Smith et al, 201120 Kodali et al, 201212 Reynolds et al 201230 |
TAVI: NA (75) SAVR: NA (65) |
TF-TAVI: 23.7 (20.1–27.3) SAVR: 12.1 (7.4–16.7) |
TF-TAVI: 5.0 (3.5–6.4) SAVR: 2.6 (0.7–4.4) |
TF-TAVI: 4.3 (2.5–6.1) SAVR: −0.3 (−2.6 to 2.1) |
TF-TAVI: 0.08 (0.04–0.11) SAVR: 0.02 (−0.02 to 0.06) |
| TA-TAVI: 12.5 (6.1–19.0) SAVR: 12.5 (5.5–19.5) |
TA-TAVI: 2.8 (0.6–5.0) SAVR: 0.5 (−2.1 to 3.0) |
TA-TAVI: −0.8 (−3.7 to 2.2) SAVR: 1.7 (−1.4 to 4.8) |
TA-TAVI: −0.02 (−0.08 to 0.03) SAVR: 0.01 (−0.04 to 0.06) |
||
|
1 year Smith et al, 201120 Reynolds et al, 201230 Mack et al, 201532 |
TAVI: 212/250 (84.8) SAVR: 196/226 (86.7) |
TF-TAVI: 28.7 (24.4–33.1) SAVR: 26.8 (21.8–31.7) |
TF-TAVI: 6.3 (4.5–8.2) SAVR: 6.1 (4.2–8.1) |
TF-TAVI: 5.0 (3.1–7.0) SAVR: 4.7 (2.4–6.9) |
TF-TAVI: 0.09 (0.05–0.12) SAVR: 0.08 (0.04–0.12) |
| TA-TAVI: 29.6 (23.2–36.1) SAVR: 21.6 (13.8–29.4) |
TA-TAVI: 7.1 (4.5–9.8) SAVR: 4.5 (1.2–7.8) |
TA-TAVI: 3.6 (0.1–7.0) SAVR: 3.9 (0.6–7.2) |
TA-TAVI: 0.06 (0.01–0.12) SAVR: 0.05 (−0.02 to 0.12) |
||
|
2 years Kodali et al, 201212 Hahn et al, 201331 |
TAVI: NA (83.9) SAVR: NA (85.2) |
NA | NA | NA | NA |
|
5 years Mack et al, 201532 |
TAVI: 85/100 (85.0) SAVR: 79/97 (81.4) |
NA | NA | NA | NA |
Abbreviations: CI, confidence interval; EQ-5D, EuroQOL 5-dimension questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; NA, not available; NYHA, New York Heart Association; SD, standard deviation; SF-12, 12-item Short Form questionnaire; SAVR, surgical aortic valve replacement; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.
a
Echocardiographic data (aortic regurgitation) were based on as-treated analysis. Quality-of-life data were estimated using random-effects growth curve models as reported by the author.